(AOF) – Pfizer announced the failure of Ciffreo, a global phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating fordadistrogen movaparvovec, its investigational mini-dystrophin gene therapy, in patients ambulatory patients with Duchenne muscular dystrophy (DMD). The study did not meet its primary endpoint of improvement in motor function in boys aged 4 to 7 years compared to placebo.
Key secondary endpoints, including 10-meter run/walk speed and time to rise from ground speed, also showed no significant difference from placebo.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
